Johnson & Johnson
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer fourth quarter worldwide growth of 19% was "primarily the result" of the buyout of Merck's equity stake in the European nonprescription pharmaceutical business, J&J reports. Inspired by strong performance from Splenda, McNeil is "continuing to look at models and new opportunities to broaden that whole nutritional area, so we've got a whole organization looking at it" reports J&J CEO William Weldon. "We do feel there's a big opportunity, especially with the needs of childhood obesity and other things that are out there today." J&J global fourth quarter sales increased 13.3% to $12.8 bil...
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: